Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T
Biotronik, Inc. · Decision date Oct 13, 2026
What did the FDA decide?
FDA's decision OK30 covers PMA supplement P070008/S183 for Biotronik's Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP and Enitra 8 HF-T cardiac resynchronization pacemakers (product code NKE). The supplement carries a 30-day notice for a process change by a manufacturer, sterilizer, packager or supplier: a change to the rework process for the manufacturing of the housing for pulse generators and ICDS. The source does not specify which rework steps, equipment, validation criteria or supplier changed.
The P070008 identifier ties the notice to an existing PMA rather than a new system approval, and the source does not state the original scope of that approval. The notice reports the manufacturer's stated purpose for a manufacturing-process change; it is not independent proof of safety or clinical effectiveness. The decision date is 2026-10-13, listed as OK30.
FDA approval order statement
a change to the rework process for the manufacturing of the housing for pulse generators and ICDS
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P070008/S183
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- Decision code
- OK30
- Decision date
- Oct 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P070008. Subsequent supplements may change the device or its indications.
FDA decision timeline
P070008 · Original PMA
STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD
P070008/S179 · Related supplement
PSW 2601.U, NEO 2601.U
P070008/S183 received
Application receipt date recorded by FDA.
P070008/S172 · Related supplement
Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
P070008/S182 · Related supplement
Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-
P070008/S181 · Related supplement
Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr
P070008/S183 · FDA decision
30-Day Notice
P070008/S177 · Related supplement
BIOexpress
P070008/S184 · Related supplement
Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR
Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | May 12, 2008 | FDA | |
PSW 2601.U, NEO 2601.UP070008/S179 | Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA | |
| Guidant Corp. | PMA approval | Jan 26, 2004 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P070008/S183
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



